Introduction

Fat tissue is not generally associated with pain. Yet, many people experience tender, painful fatty deposits around their bodies. These symptoms are often overlooked or misdiagnosed.¹

This condition is known as Dercum's disease, also commonly referred to as adiposis dolorosa. It is a rare disease characterised by painful fatty deposits (lipomas) under the skin, most commonly affecting the torso, arms, or legs.² Although the cause of Dercum’s disease is unknown, several mechanisms have been proposed to explain its development, including dysfunctions in the endocrine system and in lipid metabolism, as well as a possible autoimmune link.³ 

Pain from Dercum’s disease is often resistant to standard pain medications, leaving patients without effective relief.⁴

Understanding Dercum’s disease

Dercum’s disease mainly affects middle-aged women aged 35-50, with prevalence 5-30 times higher than in men.³

Symptoms

Symptoms vary among individuals in both type and severity, making diagnosis challenging. Commonly reported symptoms include: 

• Painful lipomas on the torso, arms, or legs²
• Generalised pain that worsens with pressure, movement or stress 
• Inflammation 
• Overweight or obesity
• Mood disturbances such as anxiety or depression
• Sleep disturbance
• Chronic fatigue or weakness²

These symptoms are nonspecific and can resemble those of other conditions. Dercum’s disease is commonly misdiagnosed as lipoedema, obesity, fibromyalgia and chronic fatigue syndrome.⁵ Differentiating Dercum’s disease from lipoedema is especially important, while both conditions cause abnormal fat accumulation, Dercum’s disease is generally more painful than lipoedema and is characterised by the presence of lipomas, a feature generally absent in lipoedema.⁶

Diagnosis

Given the absence of validated biomarkers or known genetic predisposition for Dercum’s disease.³ Diagnosis relies primarily on careful clinical evaluation of characteristic symptoms,  including overweight or obesity and chronic pain in lipomas, reported to have lasted more than three months.⁷ In cases where these symptoms are absent, diagnosis may depend on imaging studies and tissue biopsy to help exclude other conditions with similar symptoms.³

Classification

Dercum’s disease can be classified into four types: 

• Generalised diffuse- pain affects fat tissue throughout the body, with no distinct lipomas
• Generalised nodular- pain is widespread and occurs alongside multiple lipomas distributed throughout the body⁶
• Localised nodular- painful lipomas are limited to one or a few areas of the body
• Juxta-articular- painful fat deposits that occur around a joint³

Autoimmunity

Autoimmune diseases occur when the immune system, which serves as the body’s natural defense system, inappropriately attacks the body's healthy ‘self’ cells, leading to tissue damage and inflammation. Usually, the immune system can differentiate between ‘self’ and ‘non-self’, but in autoimmune diseases, this immune tolerance is lost.⁸ 

Key mechanisms include: 

• Loss of immune tolerance - the immune system no longer recognises the body's ‘self’ cells, triggering an autoimmune response⁸
• Autoantibody production - production of antibodies against its own tissues
• Chronic inflammation- chemicals released by immune cells contribute to sustained tissue damage⁸

Understanding these processes provides a basis for examining a possible autoimmune connection in Dercum’s disease.

Autoimmunity in Dercum’s disease 

Evidence from clinical studies suggests that immune system dysfunction may play a role in the development of Dercum’s disease.³

Possible autoimmune connections

In some patients, symptoms develop following infections⁹ which may stimulate an autoimmune response. This could help explain the chronic inflammation seen in Dercum’s disease. 

Small studies have also found changes in immune cells that help to regulate inflammation, including increased basophils and reduced natural killer cells.¹⁰ Together, these findings suggest the immune system may be dysregulated, and ongoing inflammation in the fatty tissue could contribute to the formation of the painful lipomas characteristic of Dercum’s disease. 

Additionally, some patients have other autoimmune diseases and experience symptoms such as inflammation and fatigue, which may indicate overlapping autoimmune mechanisms.² While this evidence is not conclusive, it supports the idea that immune dysregulation could play a role in Dercum’s disease.

Evidence against an autoimmune cause

Alternatively, some researchers have suggested that inflammation in fatty tissues could contribute to the pain seen in Dercum’s disease through stimulating the release of neuropeptides, molecules that influence pain signalling. Similar changes in neuropeptide activity are observed in other chronic pain conditions, such as fibromyalgia, which is not autoimmune in origin, suggesting that pain in Dercum’s disease may arise through non-autoimmune mechanisms.¹¹

Research strongly suggests that Dercum’s disease is not an autoimmune condition. Tissue biopsies consistently show that the lipomas are benign fatty tissue, with no significant immune cell infiltration beyond what is typically observed in patients with obesity.¹² Additionally, multiple studies have reported regular inflammatory markers found in the blood, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and broad autoimmune serologies are typically negative. ² Therefore, few findings demonstrate involvement of chronic inflammation. Cytokine and adipokine profiles have not demonstrated reproducible inflammatory signatures.²  

Overall, the current evidence indicates that inflammation is unlikely to be the primary cause of Dercum’s disease, and there is no clear indication of an underlying autoimmune mechanism.³ 

Implications

The lack of large-scale, high-quality studies limits the ability to establish reliable conclusions about the role of autoimmunity in Dercum’s disease. Current evidence is limited to small sample sizes, case reports, and pilot studies, which are insufficient to establish causality. Importantly, no biomarker has been identified with a clear association to Dercum’s disease. Further research is therefore necessary to determine whether the immune system contributes directly to its cause or whether observed immune changes are secondary to other disease mechanisms. 

Alternative proposed causes

Several non-immune mechanisms have also been proposed in the development of Dercum’s disease.² Comorbidities such as obesity, dysfunctions in the endocrine system and lipid metabolism are frequent in patients with Dercum’s disease. It is this comorbidity that may confound the interpretation of immune-related findings.¹⁰

Pain may also arise from mechanical pressure exerted by lipomas on surrounding nerves, altered metabolic function within adipose tissue, or endocrine dysregulation, rather than direct immune-mediated damage.² These alternative explanations highlight that the characteristic pain and associated symptoms of Dercum’s disease may not require an autoimmune basis, but could instead reflect overlapping metabolic and mechanical factors. 

Treatments

To date, there is no cure for Dercum’s disease, and treatment is mainly symptomatic. Management strategies are personalised based on each patient’s individual needs.⁴ 

Surgical intervention

Liposuction is widely performed for pain management, though the mechanism by which it alleviates pain is not fully understood.¹¹ Patients may experience temporary symptom improvement. However, recurrence is common, and the degree of pain relief diminishes over time.¹¹

Medicinal intervention

Standard pain medications, including non-steroidal anti-inflammatory drugs and corticosteroids, are generally inadequate in providing long-term relief of pain ² Therefore, other options, such as analgesics, antidepressants or antiseizure medication used for nerve pain, have been trialled with many patients reporting success in pain relief.²

Physical therapy

Non-surgical measures such as compression garments, manual or pneumatic compression therapy, and water-based exercise can also help to reduce swelling and provide symptomatic relief.¹³

Supportive care 

Addressing psychiatric and emotional disturbances is an equally important component of treatment. Psychological support, lifestyle modifications and patient education all play an essential role in improving quality of life.⁵

Future directions 

Treatment needs in Dercum’s disease remain largely unmet and rely on addressing current knowledge gaps to refine diagnosis and inform the development of effective therapies. 

Further research is necessary to determine the underlying cause of the disease. Studies testing existing hypotheses and the potential role of the immune system to help clarify whether Dercum’s disease shares pathways with autoimmune disorders. Conducting large-scale clinical trials is of utmost urgency to identify the most effective strategies for managing symptoms at different stages of the disease. Lastly, the development of patient registries and integration into rare disease networks will be essential for monitoring disease progression, facilitating collaborative research, and ultimately improving patient outcomes.

FAQs

Is there a cure for Dercum’s disease? 

There is no cure for Dercum’s disease. Treatments focus on managing the symptoms, alleviating pain, and improving patients' quality of life through a combination of treatment approaches. 

Can Dercum’s disease affect children?

Dercum’s disease is almost exclusively found in adults, with limited cases of children affected.⁷

What are the main symptoms of Dercum’s disease?

The most common symptoms include painful fatty deposits around the torso, arms or legs, widespread pain that worsens following pressure or movement, fatigue and weakness, sleep disturbances and various other symptoms. 

How is Dercum’s disease diagnosed?

Diagnosis relies on a clinical evaluation of characteristic symptoms, such as chronic pain in lipomas lasting over three months, as well as overweight or obesity. Imaging studies and tissue biopsies can be used to support diagnosis through exclusion of other conditions.

Summary 

Dercum’s disease is a rare, chronic disorder characterised by painful lipomas and a range of symptoms that can severely impact quality of life. While autoimmune and inflammatory mechanisms have been proposed, current evidence remains inconsistent, with most studies reporting normal inflammatory markers and no clear histological signs of immune-mediated damage. Alternative hypotheses, such as mechanical nerve compression and dysfunctions in the endocrine system and in lipid metabolism, may therefore play a greater role in symptom development. Currently, treatment is primarily symptomatic, underscoring the limited curative options and the absence of large-scale, controlled clinical trials. Future research, including studies of immune biomarkers, genetic predisposition, and long-term patient outcomes, is essential to clarify disease mechanisms and guide more effective therapies.